Acadia 3Q Loss Narrows On Revenue Boost
Stock quotes in this article:
ACAD
SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. said Monday its third-quarter loss narrowed on lower costs and a boost in revenue from its drug development partners.
The development-stage biopharmaceutical company lost $8.7 million, or 23 cents per share, compared with a loss of $15.6 million, or 42 cents per share, during the same period a year prior. Revenue surged to $2.4 million from $282,000, mainly on the company's collaboration with Biovail. Analysts expected a loss of 24 cents per share. The company is working with Biovail on pimavanserin as a potential Parkinson's disease treatment and schizophrenia therapy. They've been partners since May.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,328.89 | 1,102.47 | 2,211.69 | 35.46 |
Oil *
73.88
|
|
UP
20.63
|
UP
6.40
|
UP
31.64
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.95
|
|
+0.20%
|
+0.58%
|
+1.45%
|
+1.69%
|
Data delayed 20 minutes |














